BRD2 and breast cancer: The ultimate goal of NAT in BC patients is pCR (6), and the early prediction of NAT responsiveness and pCR status can assess the effectiveness of treatment and help clinicians adjust treatment regimens in a timely manner, thereby reducing the adverse consequences of unresponsive treatment (7).